JCR Pharma and Alexion partner on JUST-AAV gene therapy platform

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids.

Jul 9, 2025 - 06:00

JCR Pharma and Alexion partner on JUST-AAV gene therapy platform

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids.

Read the original article

Tags:

Previous Article

Microbiome Cell-Free RNA Differentiates Colorectal Cancer

CTO East Coast 2025: Navigating shifting regulatory environment hinges on close ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Beleaguered drug manufacturer Emergent cuts jobs, executive role in business shake-up

STAT+: Beleaguered drug manufacturer Emergent cuts jobs...

Aug 9, 2023

Which drugs are most likely to be approved in Non-infec...

Mar 28, 2024

NPX-267 by NextPoint Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Non-Small Cell Lu...

Jun 14, 2024